American Journal of Cardiovascular Drugs

, Volume 8, Issue 4, pp 219–231 | Cite as

Management of Ischemic Heart Disease in Patients with Chronic Kidney Disease

Review Article


Patients with chronic kidney disease (CKD) and ischemic heart disease (IHD) have strikingly high mortality rates. In the general population, there has been a reduction in the mortality and morbidity rates for IHD through the implementation of effective risk-factor-reduction programs and better interventions for patients with established IHD. No such trend has been observed in patients with end-stage kidney disease.

This review article addresses the following topics: (i) epedemiology, pathogenesis, clinical CKD patients with IHD; (ii) diagnostic modalities for IHD and their limitation in CKD patients; (iii) medical treatment options and revascularization strategies for these high-risk patients; and (iv) optimal cardiovascular risk management. Generally, in CKD patients with IHD an aggressive approach to IHD is warranted, a low threshold for diagnostic testing should be employed, and awaiting a clinical trial targeting these patients they should be considered for all proven strategies to improve outcomes.



Dr Reddan has received honoraria from Pfizer and Astra Zeneca for invited lectures. Drs Reddan and Glynn have received an honorarium from Roche for the development of guidelines for chronic kidney disease. No sources of funding were used in the preparation of this review.


  1. 1.
    United States Renal Data System: causes of death in ESRD. Am J Kidney Dis 1999; 34(2 Suppl. 1): S87–S94.Google Scholar
  2. 2.
    United States Renal Data System: patient mortality and survival in ESRD. Am J Kidney Dis 1999; 34(2 Suppl. 1): S74–S86.Google Scholar
  3. 3.
    Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32(5 Suppl. 3): S112–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Manske CL, Wang Y, Rector T, et al. Coronary revascularization in insulin-dependent diabetic patients with chronic renal failure. Lancet 1992; 340: 998–1002.PubMedCrossRefGoogle Scholar
  5. 5.
    Lippert J, Ritz E, Schwarzbeck A, et al. The rising tide of endstage renal failure from diabetic nephropathy type II: an epidemiological analysis. Nephrol Dial Transplant 1995; 10: 462–7.PubMedGoogle Scholar
  6. 6.
    Trespalacios FC, Taylor AJ, Agodoa LY, et al. Incident acute coronary syndromes in chronic dialysis patients in the United States. Kidney Int 2002; 62: 1799–805.PubMedCrossRefGoogle Scholar
  7. 7.
    Cheung AK, Sarnak MJ, Yan G, et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO study. Kidney Int 2004; 65: 2380–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Parekh RS, Zhang L, Fivush BA, et al. Incidence of atherosclerosis by race in the dialysis morbidity and mortality study: a sample of the US ESRD population. J Am Soc Nephrol 2005; 16: 1420–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Reddan DN, Szczech LA, Tuttle RH, et al. Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease. J Am Soc Nephrol 2003; 14: 2373–80.PubMedCrossRefGoogle Scholar
  10. 10.
    Henry RM, Kostense PJ, Bos G, et al. Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn Study. Kidney Int 2002; 62: 1402–7.PubMedCrossRefGoogle Scholar
  11. 11.
    U. S. Renal Data System. USRDS 2003 Annual Report: atlas of end-stage renal disease in the United States. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2003.Google Scholar
  12. 12.
    Jokin N, Hase H, Nakamura R, et al. Onset of coronary artery disease prior to initiation of hemodialysis in patients with end-stage renal disease. Nephrol Dial Transplant 1997; 12: 718–23.CrossRefGoogle Scholar
  13. 13.
    Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998; 32: 853–906.PubMedCrossRefGoogle Scholar
  14. 14.
    Wright RS, Reeder GS, Herzog CA, et al. Acute myocardial infarction and renal dysfunction: a high risk combination. Ann Intern Med 2002; 137: 563–70.PubMedGoogle Scholar
  15. 15.
    Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998; 339: 799–805.PubMedCrossRefGoogle Scholar
  16. 16.
    Herzog CA. Acute MI in dialysis patients: how can we improve the outlook. J Crit Illn 1999; 14: 613–21.Google Scholar
  17. 17.
    Rosamond WD, Chambless LE, Folsom AR, et al. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease. N Engl J Med 1998; 339: 861–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Luke RG. Chronic renal failure: a vasculopathic state. N Engl J Med 1998; 339: 841–3.PubMedCrossRefGoogle Scholar
  19. 19.
    Vaitkus PT. Current status of prevention, diagnosis, and management of coronary artery disease in patients with kidney failure. Am Heart J 2000; 139: 1000–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Venkatesan J, Henrick WL. Anemia, hypertension, and myocardial dysfunction in end-stage renal disease. Semin Nephrol 1997; 17: 257–69.PubMedGoogle Scholar
  21. 21.
    Tvedegaard E, Kamstrup O. The effect of chronic renal failure in rabbits on plasma lipids and the concentration of cholesterol, calcium and phosphate in the aortic wall. Proc Eur Dial Transplant Assoc 1980; 17240–6.Google Scholar
  22. 22.
    Oh J, Wunsch R, Turzer M, et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 2002; 106(1): 100–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Stancanelli B, Malatino LS, Malaponte G, et al. Pulse pressure is an independent predictor of aortic stiffness in patients with mild to moderate chronic kidney disease. Kidney Blood Press Res 2007; 30: 283–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Aronow WS, Ahn C, Mercando AD, et al. Prevalence of coronary artery disease, complex ventricular arrythmias, and silent myocardial ischaemia and incidence of new coronary artery events in older persons with chronic renal insufficiency and with normal renal function. Am J Cardiol 2000; 86: 1142–3.PubMedCrossRefGoogle Scholar
  25. 25.
    Zawada ET, Stinson JB, Done G. New perspectives on coronary artery disease in haemodialysis patients. South Med J 1982; 75: 694–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Herzog CA. Diagnosis and treatment of ischemic heart disease in dialysis patients. Curr Opin Nephrol Hypertens 1997; 6: 558–65.PubMedCrossRefGoogle Scholar
  27. 27.
    de Lemos JA, Hillis LD. Diagnosis and management of coronary artery disease in patients with end-stage renal disease on hemodialysis. J Am Soc Nephrol 1996; 7: 2044–54.PubMedGoogle Scholar
  28. 28.
    Goldsmith DJ, Covic A. Coronary artery disease in ureamia: etiology, diagnosis and therapy. Kidney Int 2001; 60: 2059–78.PubMedCrossRefGoogle Scholar
  29. 29.
    Amann K, Ritz E. Cardiac disease in chronic uremia: pathophysiology. Adv Renal Replace Ther 1997; 4: 212–24.Google Scholar
  30. 30.
    US Renal Data System. USRDS 2001 annual data report. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2001.Google Scholar
  31. 31.
    Amann K, Rychlik I, Miltenberger-Milteny G, et al. Left ventricular hypertrophy in renal failure. Kidney Int 1998; 68: S78–85.CrossRefGoogle Scholar
  32. 32.
    Kasiske BL, Cangro CB, Hariharan S, et al. The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant 2002; 1 Suppl. 2: 1–95.Google Scholar
  33. 33.
    Gaston RS, Danovitch GM, Adams PL, et al. The report of a National Conference on the Wait List for Kidney Transplantation. Am J Transplant 2003; 3: 775–85PubMedCrossRefGoogle Scholar
  34. 34.
    K/DOQI Clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45 Suppl. 3: S1.Google Scholar
  35. 35.
    Gill JS, Ma I, Landsberg D, et al. Cardiovascular events and investigation in patients who are awaiting cadaveric kidney transplantation. J Am Soc Nephrol 2005; 16: 808–16.PubMedCrossRefGoogle Scholar
  36. 36.
    Savonitto S, Ardissino D, Granger CB, et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA 1999; 281: 707–13.PubMedCrossRefGoogle Scholar
  37. 37.
    Charytan DM, Setoguchi S, Solomon DH, et al. Clinical presentation of myocardial infarction contributes to lower use of coronary angiography in patients with chronic kidney disease. Kidney Int 2007; 71: 938–45.PubMedCrossRefGoogle Scholar
  38. 38.
    Kanderian AS, Francis GS. Cardiac troponins and chronic kidney disease. Kidney Int 2006; 69: 1112–4.PubMedCrossRefGoogle Scholar
  39. 39.
    Van Lente F, McErlean ES, DeLuca SA, et al. Ability of troponin to predict adverse outcomes in patients with renal insufficiency and suspected acute coronary syndromes: a case matched study. J Am Coll Cardiol 1999; 33: 471–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Hedayati SS, Szczech LA. The evaluation of underlying cardiovascular disease among patients with end-stage renal disease. Adv Chronic Kidney Dis 2004; 11: 246–253.PubMedCrossRefGoogle Scholar
  41. 41.
    Jaffe AS, Ritter C, Meltzer V, et al. Unmasking artifactual increases in creatine kinase isoenzymes in patients with renal failure. J Lab Clin Med 1984; 104: 193–202.PubMedGoogle Scholar
  42. 42.
    Robbins MJ, Epstein EM, Shah S. Creatine kinase subform analysis in haemodialysis patients without acute coronary syndromes. Nephron 1997; 76: 296–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Croitoru M, Taegtmeyer H. Spurious rises in troponin T in end-stage renal disease. Lancet 1995; 346: 1558.CrossRefGoogle Scholar
  44. 44.
    Bhayana V, Gougoulias T, Cohoe S, et al. Discordance between results for serum troponin T and troponin I in renal disease. Clin Chem 1995; 41: 312–7.PubMedGoogle Scholar
  45. 45.
    Martin GS, Becker BN, Schulman G. Cardiac troponin-I accurately predicts myocardial injury in renal failure. Nephrol Dial Transplant 1998; 13: 1709–12.PubMedCrossRefGoogle Scholar
  46. 46.
    McLaurin MD, Apple FS, Falahati A, et al. Cardiac troponin I and creatine kinase-MB mass to rule out myocardial injury in hospitalized patients with renal insufficiency. Am J Cardiol 1998; 82: 973–5.PubMedCrossRefGoogle Scholar
  47. 47.
    Aviles RJ, Askari AT, Ohman EM, et al. Troponin T levels in patients with acute coronary syndromes, with and without renal dysfunction. N Engl J Med 2002; 346: 2047–52.PubMedCrossRefGoogle Scholar
  48. 48.
    Apple FS, Murakami MM, Pearce LA, et al. Predictive value of cardiac troponin I and T for subsequent death in endstage renal disease. Circulation 2002; 106: 2941–5.PubMedCrossRefGoogle Scholar
  49. 49.
    Lindahl B, Venge P, Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long term antithrombotic protection. J Am Coll Cardiol 1997; 29: 43–8.PubMedCrossRefGoogle Scholar
  50. 50.
    Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344: 1879–87.PubMedCrossRefGoogle Scholar
  51. 51.
    Fuchs S, Kornowski R, Mehran R, et al. Prognostic value of cardiac troponin-I levels following catheter-based coronary interventions. Am J Cardiol 2000; 85: 1077–82.PubMedCrossRefGoogle Scholar
  52. 52.
    Gruberg L, Mintz GS, Mehran R, et al. The prognostic implications of further renal function deterioration within 48h of interventional coronary procedures in patients with pre- existent chronic renal insufficiency. J Am Coll Cardiol 2000; 36: 1542–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Tepel M, van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343: 180–4.PubMedCrossRefGoogle Scholar
  54. 54.
    Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 2002; 40: 1383–8.PubMedCrossRefGoogle Scholar
  55. 55.
    Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 2002; 89: 356–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Marenzi G, Assanelli E, Marana I, et al. N Acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 2006; 354: 2773–82.PubMedCrossRefGoogle Scholar
  57. 57.
    Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002; 162: 329–36.PubMedCrossRefGoogle Scholar
  58. 58.
    Aspelin P, Aubry P, Fransson SG, et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003; 348: 491–9.PubMedCrossRefGoogle Scholar
  59. 59.
    Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085–98.PubMedCrossRefGoogle Scholar
  60. 60.
    Fellström B, Zannad F, Schmieder R, et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: design and rationale of the AURORA study. Curr Control Trials Cardiovasc Med 2005; 6: 9.PubMedCrossRefGoogle Scholar
  61. 61.
    Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 2003; 42: 201–8.PubMedCrossRefGoogle Scholar
  62. 62.
    Shlipak MG, Heidenreich PA, Noguchi H, et al. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 2002; 137: 555–62.PubMedGoogle Scholar
  63. 63.
    Beattie JN, Soman SS, Sandberg KR, et al. Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction. Am J Kidney Dis 2001; 37: 1191–200.PubMedCrossRefGoogle Scholar
  64. 64.
    Sjøgren P, Dragsted L, Christensen CB. Myoclonus and spasms during treatment with high doses of intravenous morphine in renal failure. Acta Anaesthesiol Scand 1993; 37: 780–2.PubMedCrossRefGoogle Scholar
  65. 65.
    Bunn R, Ashley C. Renal drug handbook. Oxford: Radcliffe Medical Press, 1999.Google Scholar
  66. 66.
    Chauvin M, Sandouk P, Sherrmann JM, et al. Morphine pharmacokinetics in renal failure. Anaesthesiology 1987; 66: 327–31.CrossRefGoogle Scholar
  67. 67.
    Davies G, Kingswood C, Street M. Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacokinet 1996; 31: 410–22.PubMedCrossRefGoogle Scholar
  68. 68.
    McCullough PA, Sandberg KR, Borzak S, et al. Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J 2002; 144: 226–32.PubMedCrossRefGoogle Scholar
  69. 69.
    Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494–502.PubMedCrossRefGoogle Scholar
  70. 70.
    Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina). Circulation 1999; 99: 2829–48.PubMedCrossRefGoogle Scholar
  71. 71.
    Januzzi JL, Snapinn SM, DiBattiste PM, et al. Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency. Circulation 2002; 105: 2361–6.PubMedCrossRefGoogle Scholar
  72. 72.
    Reddan DN, O’Shea JC, Sarembock IJ, et al. Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial). Am J Cardiol 2003; 91: 17–21.PubMedCrossRefGoogle Scholar
  73. 73.
    Jeremias A, Bhatt DL, Chew DP, et al. Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency. Am J Cardiol 2002; 89: 1209–11.PubMedCrossRefGoogle Scholar
  74. 74.
    Best PJ, Lennon R, Gersh BJ, et al. Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. Am Heart J 2003; 146: 345–50.PubMedCrossRefGoogle Scholar
  75. 75.
    Frilling B, Zahn R, Fraiture B, et al. Comparison of efficacy and complication rates after percutaneous coronary interventions in patients with and without renal insufficiency treated with abciximab. Am J Cardiol 2002; 89: 450–2.PubMedCrossRefGoogle Scholar
  76. 76.
    Hirsch J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001 Jan; 119(I Suppl.): 64S–94S.CrossRefGoogle Scholar
  77. 77.
    Brophy DF, Wazny LD, Gehr TW, et al. The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease. Pharmacotherapy 2001; 21: 169–74.PubMedCrossRefGoogle Scholar
  78. 78.
    Cadroy Y, Pourrat J, Baladre MF, et al. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res 1991; 63: 385–90.PubMedCrossRefGoogle Scholar
  79. 79.
    Gerlach AT, Pickworth KK, Seth SK, et al. Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy 2000; 20: 771–5.PubMedCrossRefGoogle Scholar
  80. 80.
    Lim W, Cook DJ, Crowther MA. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a metaanalysis of randomized trials. J Am Soc Nephrol 2004; 15: 3192–206.PubMedCrossRefGoogle Scholar
  81. 81.
    Hirsch J, Warkentin TE, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998; 114: 489S–510S.CrossRefGoogle Scholar
  82. 82.
    Hassan WM, Flaker GC, Feutz C, et al. Improved anticoagulation with a weight adjusted heparin nomogram in patients with acute coronary syndromes: a randomised trial. J Thromb Thrombolysis 1995; 2: 245–9.PubMedGoogle Scholar
  83. 83.
    Boneau B, Caranobe C, Sie P. Pharmacokinetics of heparin and low-molecular weight heparin. Baillieres Clin Haematol 1990; 3: 531–44.CrossRefGoogle Scholar
  84. 84.
    House AK, Potter JM, Smith PA, et al. Heparinization an aortic surgery. J Cardiovasc Surg (Torino) 1988; 29: 707–11.Google Scholar
  85. 85.
    Hirsch J, Anand SS, Halperin JL, et al. Guide to anticoagulation therapy: heparin. A statement for healthcare professionals from the American Heart Association. Circulation 2001; 103: 2994–3018Google Scholar
  86. 86.
    The Assessment of the Safety and Efficacy of New Thrombolytic Regimen (ASSENT-3) Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358: 605–13.CrossRefGoogle Scholar
  87. 87.
    Robson R. The use of bivalirudin in patients with renal impairment. J Invasive Cardiol 2000; 12 Suppl. F: 33F–36F.PubMedGoogle Scholar
  88. 88.
    Herzog CA, Ma JZ, Collins AJ. Long-term survival of dialysis patients receiving thrombolytic therapy for acute myocardial infarction in the U.S. [abstract]. Circulation 1999; 100 Suppl. I: I–304Google Scholar
  89. 89.
    The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition. Lancet 2001; 357: 1905–14.CrossRefGoogle Scholar
  90. 90.
    The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996; 335: 217–25.CrossRefGoogle Scholar
  91. 91.
    Herzog CA, Ma JZ, Collins AJ. Long-term outcome of dialysis patients in the United States with coronary revascularization procedures. Kidney Int 1999; 56: 324–32.PubMedCrossRefGoogle Scholar
  92. 92.
    Szczech LA, Reddan DN, Owen WF, et al. Differential survival after coronary revascularization procedures among patients with renal insufficiency. Kidney Int 2001; 60: 292–9.PubMedCrossRefGoogle Scholar
  93. 93.
    Rinehart A, Herzog C, Collins A, et al. A comparison of coronary angioplasty and coronary artery bypass grafting outcomes in chronic dialysis patients. Am J Kidney Dis 1995; 25: 281–90.PubMedCrossRefGoogle Scholar
  94. 94.
    Simsir SA, Kohlman-Trigoboff D, Flood R, et al. A comparison of coronary artery bypass grafting and percutaneous transluminal coronary angioplasty in patients on hemodialysis. Cardiovasc Surg 1998; 6: 500–5.PubMedCrossRefGoogle Scholar
  95. 95.
    Koyanagi T, Nishida H, Kitamura M, et al. Comparison of clinical outcomes of coronary artery bypass grafting and percutaneous transluminal coronary angioplasty in renal dialysis patients. Ann Thorac Surg 1996; 61: 1793–6.PubMedCrossRefGoogle Scholar
  96. 96.
    Legrand VMG, Serruys PW, Unger F, et al. Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease. Circulation 2004; 109: 1114–20.PubMedCrossRefGoogle Scholar
  97. 97.
    Hemmelgarn BR, Southern D, Culleton BF, et al. Survival after coronary revascularization among patients with kidney disease. Circulation 2004; 110: 1890–5.PubMedCrossRefGoogle Scholar
  98. 98.
    Rubenstein MH, Harrell LC, Sheynberg BV, et al. Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era? Circulation 2000; 102: 2966–72.PubMedCrossRefGoogle Scholar
  99. 99.
    Liu JY, Birkmeyer NJO, Sanders JH, et al. Risks of morbidity and mortality in dialysis patients undergoing coronary artery bypass surgery. Circulation 2000; 102: 2973–7.PubMedCrossRefGoogle Scholar
  100. 100.
    Morice M, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimuseluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773–80.PubMedCrossRefGoogle Scholar
  101. 101.
    Morice M, Serruys P, Costantini C, et al. Ischemic Heart Disease and Renal Failure: two-year follow-up of the RAVEL study. A randomized study with the sirolimus-eluting Bx VELOCITY stent in the treatment of patients with denovo native coronary artery lesions [abstract]. J Am Coll Cardiol 2003; 41 Suppl. A: 32A.CrossRefGoogle Scholar
  102. 102.
    Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents. Part I. Circulation 2003; 107: 2274–9.Google Scholar
  103. 103.
    Halkin A, Mehran R, Casey CW, et al. Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV trial. Am Heart J 2005; 150: 1163–70PubMedCrossRefGoogle Scholar
  104. 104.
    K/DOQI Clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45 Suppl. 3: S1.Google Scholar
  105. 105.
    Tonelli M, Jose P, Curhan G, et al. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomized trial. BMJ 2006; 332: 1426.PubMedCrossRefGoogle Scholar
  106. 106.
    Anavekar NS, McMurray JJV, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285–95.PubMedCrossRefGoogle Scholar
  107. 107.
    Al Suwaidi J, Reddan DN, Williams K, et al. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 2002; 106: 974–80.CrossRefGoogle Scholar
  108. 108.
    Hemmelgarn BR, Southern D, Humphries KH, et al. Refined characterization of the association between kidney function and mortality in patients undergoing cardiac catheterization. Eur Heart J 2006; 27: 1191–7.PubMedCrossRefGoogle Scholar
  109. 109.
    Henry RMA, Kamp O, Kostense PJ, et al. Mild renal insufficiency is associated with increased left ventricular mass in men, but not in women: an arterial stiffness-related phenomenon: the Hoorn Study. Kidney Int 2005; 68(2): 673–9.PubMedCrossRefGoogle Scholar
  110. 110.
    Muntner P, He J, Hamm L, et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002; 13: 745–53.PubMedGoogle Scholar
  111. 111.
    Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296–305.PubMedCrossRefGoogle Scholar
  112. 112.
    Shlipak MG, Fried LF, Crump C, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003; 107: 87–92.PubMedCrossRefGoogle Scholar
  113. 113.
    Muntner P, Hamm LL, Kusek JW, et al. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 2004; 140: 9–17.PubMedGoogle Scholar
  114. 114.
    Hsu C-Y, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the third national health and nutrition epidemiology survey. J Am Soc Nephrol 2002; 13: 504–10.PubMedCrossRefGoogle Scholar
  115. 115.
    Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients: a link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002; 39: 695–701.PubMedCrossRefGoogle Scholar
  116. 116.
    Perazella MA, Khan S. Increased mortality in chronic kidney disease: a call to action. Am J Med Sci 2006; 331: 150–3PubMedCrossRefGoogle Scholar
  117. 117.
    Cardiovascular health strategy group. building healthier hearts. Dublin: The Stationery Office, 1999.Google Scholar
  118. 118.
    Wood D, DeBacker G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998; 19: 1434–503.CrossRefGoogle Scholar
  119. 119.
    Levey AS. Measurement of renal function in chronic renal disease. Kidney Int 1990; 38: 167–84.PubMedCrossRefGoogle Scholar
  120. 120.
    Swedko PJ, Clark HD, Paramsothy K, et al. Serum creatinine is an inadequate screening test for renal failure in elderly patients. Arch Intern Med 2003; 163: 356–60.PubMedCrossRefGoogle Scholar
  121. 121.
    Smith H. Diseases of the kidney and urinary tract. the kidney: structure and function in health and disease. New York: Oxford University Press, 1951: 836–87.Google Scholar
  122. 122.
    McCullough PA. Why is chronic kidney disease the 'spoiler’ for cardiovascular outcomes? J Am Coll Cardiol 2003; 41: 725–8.PubMedCrossRefGoogle Scholar
  123. 123.
    Ezekowitz J, McAlister FA, Humphries KH, et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 2004; 44: 1587–92.PubMedCrossRefGoogle Scholar
  124. 124.
    Biesenbach G, Zazgornik J. Influence of smoking on the survival rate of diabetic patients requiring hemodialysis. Diabetes Care 1996; 19: 625–628.PubMedCrossRefGoogle Scholar
  125. 125.
    Wilson K, Gibson N, Willan A, et al. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med 2000; 160: 939–44.PubMedCrossRefGoogle Scholar
  126. 126.
    Levis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–60.CrossRefGoogle Scholar
  127. 127.
    Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355: 253–9.Google Scholar
  128. 128.
    Chobanian AV, Bakris GI, Black H, for the National Heart, Lung, And Blood Institute Joint National Committee On Prevention, Detection, Evaluation, And Treatment Of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: the Seventh Report Of The Joint National Committee On Prevention, Detection, Evaluation, And Treatment Of High Blood Pressure: the JNC 7 Report. JAMA 2003; 289: 2560–72.PubMedCrossRefGoogle Scholar
  129. 129.
    Hampl H, Sternberg C, Berweck S, et al. Regression of left ventricular hypertrophy in hemodialysis patients is possible. Clin Nephrol 2002; 58 Suppl. 1: S73–96.PubMedGoogle Scholar
  130. 130.
    Li PK, Chow KM, Wong TY, et al. Effects of an angiotensin converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis: a randomized, controlled study. Ann Intern Med 2003; 139: 105–12.PubMedGoogle Scholar
  131. 131.
    Bakris GL. Role For beta-blockers in the management of diabetic kidney disease. Am J Hypertens 2003; 16: 7S–12S.PubMedCrossRefGoogle Scholar
  132. 132.
    Cice G, Ferrara L, D’Andrea A, et al. Carvedilol increases two year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003; 41: 1438–44.PubMedCrossRefGoogle Scholar
  133. 133.
    Marchi F, Cirello C. Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria: a multicenter, randomized, open-label, controlled study versus atenolol. Adv Ther 1995; 12: 212–21.PubMedGoogle Scholar
  134. 134.
    Luft FC, Agarwal B. Microalbuminuria as a predictive factor for cardiovascular events. J Cardiovasc Pharmacol 1999; 33 Suppl. 1: S11–5.PubMedCrossRefGoogle Scholar
  135. 135.
    Dupont AG, Van der Niepen P, Taeymans Y, et al. Effect of carvedilol on ambulatory blood pressure, renal hemodynamics, and cardiac function in essential hypertension. J Cardiovasc Pharmacol 1987; 10 Suppl. 11: S130–6.PubMedGoogle Scholar
  136. 136.
    Borchard U. Pharmacokinetics of beta-adrenoreceptor blocking agents: clinical significance of hepatic and/or renal clearance. Clin Physiol Biochem 1990; 8 Suppl. 2: 28–34.PubMedGoogle Scholar
  137. 137.
    Buemi M, Senatore M, Corica F, et al. Statins and progressive renal disease. Med Res Rev 2002; 22: 76–84.PubMedCrossRefGoogle Scholar
  138. 138.
    Oda H, Keane WF. Recent advances in statins and the kidney. Kidney Int 1999; 71 Suppl.: S2–5.CrossRefGoogle Scholar
  139. 139.
    Wanner C, Krane V, März W, et al., for the German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238–48.PubMedCrossRefGoogle Scholar
  140. 140.
    Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59: 260–9.PubMedCrossRefGoogle Scholar
  141. 141.
    Tonelli M, Moyé L, Sacks FM, et al., on behalf of the Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003; 138: 98–104.PubMedGoogle Scholar
  142. 142.
    Bianchi S, Bigazzi R, Caiazza A, et al. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003; 41: 565–70.PubMedCrossRefGoogle Scholar
  143. 143.
    Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutrition-inflammation-cachexia syndrome. J Am Soc Nephrol 2007; 18(1): 304–11PubMedCrossRefGoogle Scholar
  144. 144.
    Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–97.CrossRefGoogle Scholar
  145. 145.
    Kasiske B, Cosio FG, Beto J, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 2004; 4 Suppl. 7: 13–53.PubMedCrossRefGoogle Scholar
  146. 146.
    Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 2003; 84: S207–10.PubMedCrossRefGoogle Scholar
  147. 147.
    Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 2002; 162: 2197–202.PubMedCrossRefGoogle Scholar
  148. 148.
    Winchester JF. Therapeutic uses of aspirin in renal diseases. Am J Kidney Dis 1996; 28 Suppl. 1: S20–23.PubMedCrossRefGoogle Scholar
  149. 149.
    Van Guidener C, Stam F, Stehouwer CD. Homocysteine metabolism in renal failure. Kidney Int 2001; 78 Suppl. 59: S234–237.CrossRefGoogle Scholar
  150. 150.
    Moustapha A, Naso A, Nahlawi M, et al. Prospective study of hyperhomocystinemia as an adverse cardiovascular risk factor inend-stage renal disease. Circulation 1998; 97: 138–41.PubMedCrossRefGoogle Scholar
  151. 151.
    Shemin D, Bostom Ag, Seihub J. Treatment of hyperhomocystinemia in end-stage renal disease. Am J Kidney Dis 2001; 38 Suppl. 1: S91–4.PubMedCrossRefGoogle Scholar
  152. 152.
    Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomized placebo-controlled trial. Lancet 2000; 356: 1213–8.PubMedCrossRefGoogle Scholar
  153. 153.
    Tepel M, van der Giet M, Statz M, et al. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003; 107: 992–5.PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  1. 1.Department of Medicine, Division of NephrologyNational University of IrelandGalwayIreland
  2. 2.Department of General PracticeNational University of IrelandGalwayIreland
  3. 3.Unit 1Merlin Park University HospitalGalwayIreland

Personalised recommendations